Determining the Frequency Distribution of Ocular Manifestations in Multiple Sclerosis Patients

Authors

1 Department of Ophthalmology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Abstract

Introduction: Multiple Sclerosis (MS) is the most common disabling neurological disease in young people. It is estimated that about 2 million people in the world suffer from this disease. Ocular involvement is one of the most prevalent clinical signs of MS. It is said that 25% of individuals suffer from vision problems during the development of disease. Therefore, this study was conducted in Yazd due to its climate changes and lack of study in this regard.
Methods: This study is a cross sectional type, conducted with the aim of studying the frequency of eye symptoms in MS patients referring to the Shahid Sadoughi Yazd ophthalmology Clinic from 2012 to 2014. The Sample size includes 150 patients who referred to the clinic. The tool for gathering information was a questionnaire. After gathering 150 samples, all the data was coded and entered into the computer. Results were analyzed by SPSS18, descriptive statistics, and Chi 2 test.
Results: The examined patients included 150 MS patients aged 33.48 years on average and with 28.43 years the onset age of disease examined. This study shows that blurred vision rate of 78.7% and the diplopia rate of 56% were the most prevalent vision complaints of patients from the starting the disease until examination. Optic atrophy with 14.7% and optic neuritis with 12% were the most common ocular findings in the examination.
Conclusion: We can conclude that vision disorders are the common consequences of MS. These disorders are accompanied by factors such as age, sex, residence, and family background. Therefore, it is necessary to take the patients’ demographic characteristics into account in their initial examinations.

Keywords


1.   Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. The Lancet Neurology. 2005;4(2):111-21.

2.   Greenberg D, Aminoff M, Simon R. Clinical Neurology 8/E: McGraw Hill Professional; 2012.

3.   Sakai RE, Feller DJ, Galetta KM, Galetta SL, Balcer LJ. Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. Journal of neuro-ophthalmology: the official journal of the North American Neuro-Ophthalmology Society. 2011;31(4):362-73.

4.   Adams R, Victor M, Ropper A. Principle of neurology 7th ed. McGrawhill; 2005.

5.   Fischer LG. The ocular manifestations of multiple sclerosis. Journal of the American Optometric Association. 1977;48(12):1511-5.

6.   Chen L, Gordon LK. Ocular manifestations of multiple sclerosis. Current opinion in ophthalmology. 2005;16(5):315-20.

7.   JM R. Ocular problems in early stages of multiple sclerosis. Bull soc belge ophtalmol. 2009;313:65-8.

8.   Alroughani R, Ahmed SF, Al-Hashel J. Demographics and clinical characteristics of multiple sclerosis in Kuwait. European neurology. 2014;72(3-4):181-5.

9.   El-Salem K, Al-Shimmery E, Horany K, Al-Refai A, Al-Hayk K, Khader Y. Multiple sclerosis in Jordan: A clinical and epidemiological study. Journal of neurology. 2006;253(9):1210-6.

10. Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M. Pregnancy, sex and hormonal factors in multiple sclerosis. Multiple sclerosis. 2014;20(5):527-36.

11. Granieri E. Exogeneous factors in the aetiology of multiple sclerosis. Journal of neurovirology. 2000;6 Suppl 2:S141-6.

12. Fernandez-Perez MJ, Barakat O, Garcia-Moreno JM, Lucas M, Navarro G, Gata JM, et al. [Clinical features of familial multiple sclerosis in Spain]. Revista de neurologia. 1999;29(8):693-6.

13. Anton Aranda E, Martinez-Lage JM, Maravi Petri E, Gallego Cullere J, de Castro P, Villanueva Eusa JA. [Epidemiology and clinical evolutionary aspects of multiple sclerosis in Navarra]. Neurologia (Barcelona, Spain). 1991;6(5):160-9.

14. Hoang PD, Gandevia SC, Herbert RD. Prevalence of joint contractures and muscle weakness in people with multiple sclerosis. Disability and rehabilitation. 2014;36(19):1588-93.

15. Sidhom Y, Damak M, Riahi A, Hizem Y, Mrissa R, Mhiri C, et al. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course? Journal of the neurological sciences. 2014;343(1-2):110-4.